ChemoCentryx
CCXI
#3555
Rank
NZ$6.47 B
Marketcap
NZ$90.02
Share price
0.00%
Change (1 day)
35.18%
Change (1 year)

Revenue for ChemoCentryx (CCXI)

Revenue in 2022 (TTM): NZ$55.72 Million

According to ChemoCentryx's latest financial reports the company's current revenue (TTM ) is NZ$64.4 Million. In 2021 the company made a revenue of NZ$46.7 Million a decrease over the revenue in the year 2020 that were of NZ$89.24 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for ChemoCentryx from 2011 to 2022

Annual revenue

Year Revenue Change
2022 (TTM) NZ$55.72 M19.31%
2021 NZ$46.7 M-47.67%
2020 NZ$89.24 M67.18%
2019 NZ$53.38 M-16.48%
2018 NZ$63.91 M-44.97%
2017 NZ$0.11 B603.65%
2016 NZ$16.5 M
2015 N/A
2014 N/A-100%
2013 NZ$7.37 M11.95%
2012 NZ$6.58 M-83.77%
2011 NZ$40.58 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Biogen
BIIB
NZ$17.42 B 26,958.87%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$103.26 B 160,233.33%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$73.32 B 113,751.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
Bristol-Myers Squibb
BMY
NZ$83.16 B 129,023.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
NZ$159.54 B 247,612.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$62.28 B 96,596.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$108.70 B 168,679.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$29.04 B 44,996.77%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Merck
MRK
NZ$111.21 B 172,574.73%๐Ÿ‡บ๐Ÿ‡ธ USA